首页> 美国卫生研究院文献>British Medical Journal >Intranasal treatment with luteinising hormone releasing hormone agonist in women with endometriosis.
【2h】

Intranasal treatment with luteinising hormone releasing hormone agonist in women with endometriosis.

机译:黄体激素释放激素激动剂对子宫内膜异位症患者进行鼻内治疗。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

An agonist analogue of luteinising hormone releasing hormone (buserelin) was successfully used to treat women with endometriosis. A dose of 200 micrograms administered intranasally thrice daily was found to be effective in five patients, in whom the endometriotic lesions resolved after six months' treatment. Failure occurred in a sixth patient, who received only 400 micrograms once daily. Anovulation was induced in all subjects together with suppression of menstruation after the first month of treatment. Symptoms of abdominal pain, dysmenorrhoea, and dyspareunia were relieved during treatment, and one previously infertile patient conceived within two months of stopping treatment. No side effects were reported with this dosage, and the results suggest a new form of treatment for patients with endometriosis.
机译:黄体生成激素释放激素(buserelin)的激动剂类似物已成功用于治疗子宫内膜异位症的妇女。每天两次鼻腔给药200微克的剂量对5例患者有效,其中6个月的治疗后子宫内膜异位病变得以缓解。第六例患者发生衰竭,该患者每天仅接受400微克。在治疗的第一个月后,所有受试者都出现了无排卵现象,同时也抑制了月经。在治疗期间,腹痛,痛经和痛经的症状得到缓解,并且一名停止治疗的不育患者在停止治疗后的两个月内受孕。该剂量未见副作用,结果提示子宫内膜异位症患者可以采用新的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号